Optimization of flow cytometric measurement of ZAP-70 in chronic lymphocytic leukemia

Cytometry Part B - Clinical Cytometry

Volumn 74, Issue 2, 2008, Pages 118-127

  Preobrazhensky, Sergey N ^a   Bahler, David W ^b  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

CLL, scatchard analysis; Flow cytometry; ZAP 70

Indexed keywords

ANTIGEN; DYE; FLUORESCEIN ISOTHIOCYANATE; PROTEIN; PROTEIN ANTIBODY; SAPONIN; TRITON X 100; UNCLASSIFIED DRUG; ZETA CHAIN ASSOCIATED PROTEIN 70;

ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION (PARAMETERS); FALSE NEGATIVE RESULT; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; LEUKEMIA CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCATCHARD PLOT; STAINING; T LYMPHOCYTE;

ANTIBODIES; ANTIBODY SPECIFICITY; B-LYMPHOCYTES; BINDING, COMPETITIVE; BIOLOGICAL MARKERS; CELL SURVIVAL; FLOW CYTOMETRY; HUMANS; HYDRAZINES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE COUNT; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 42549121038     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20378     Document Type: Article

References (35)

1. Elder ME, Lin D, Clever J, Chan AC, Hope TJ, Weiss A, Parslow TG. Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase. Science 1994;264:1596-1599.
2. Iwashima M, Irving BA, van Oers NS, Chan AC, Weiss A. Sequential interactions of the TCR with two distinct cytoplasmic tyrosine kinases. Science 1994;263:1136-1139.
3. Bene MC. What is ZAP-70? Cytometry B Clin Cytom 2006;70B:204-208.
4. Hamblin AD, Hamblin TJ. Functional and prognostic role of ZAP-70 in chronic lymphocytic leukaemia. Expert Opin Ther Targets 2005;9: 1165-1178.
5. Orchard J, Ibbotson R, Best G, Parker A, Oscier D. ZAP-70 in B cell malignancies. Leuk Lymphoma 2005;46:1689-1698.
6. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L, Pickeral OK, Rassenti LZ, Powell J, Botstein D, Byrd JC, Grever MR, Cheson BD, Chiorazzi N, Wilson WH, Kipps TJ, Brown PO, Staudt LM. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-1647.
7. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Stetler-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944-4951.
8. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marce S, Lopez-Guillermo A, Campo E, Montserrat E. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-1775.
9. Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, Hamblin TJ, Staudt LM, Oscier DG. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363: 105-111.
10. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves A, Weiss A, Kipps TJ. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893-901.
11. Del Principe MI, Del Poeta G, Buccisano F, Maurillo L, Venditti A, Zucchetto A, Marini R, Niscola P, Consalvo MA, Mazzone C, Ottaviani L, Panetta P, Bruno A, Bomben R, Suppo G, Degan M, Gattei V, de Fabritiis P, Cantonetti M, Lo Coco F, Del Principe D, Amadori S. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 2006;108:853-861.
12. Letestu R, Rawstron A, Ghia P, Villamor N, Leuven NB, Boettcher S, Buhl AM, Duerig J, Ibbotson R, Kroeber A, Langerak A, Le Garff-Tavernier M, Mockridge I, Morilla A, Padmore R, Rassenti L, Ritgen M, Shehata M, Smolewski P, Staib P, Ticchioni M, Walker C, Ajchenbaum-Cymbalista F. Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process. Cytometry B Clin Cytom 2006;70B:309-314.
13. Best OG, Ibbotson RE, Parker AE, Davis ZA, Orchard JA, Oscier DG. ZAP-70 by flow cytometry: A comparison of different antibodies, anticoagulants, and methods of analysis. Cytometry B Clin Cytom 2006;70B:235-241.
14. Wiestner A. Flow cytometry for ZAP-70: New colors for chronic lymphocytic leukemia. Cytometry B Clin Cytom 2006;70B:201-203.
15. Marti G, Orfao A, Goolsby C. ZAP-70 in CLL: Towards standardization of a biomarker for patient management: History of clinical cytometry special issue. Cytometry B Clin Cytom 2006;70B:197-200.
16. Bojarska-Junak A, Giannopoulos K, Kowal M, Dmoszynska A, Rolinski J. Comparison of methods for determining zeta-chain associated protein-70 (ZAP-70) expression in patients with B-cell chronic lymphocytic leukemia (B-CLL). Cytometry B Clin Cytom 2006;70B:293-301.
17. Shankey TV, Forman M, Scibelli P, Cobb J, Smith CM, Mills R, Holdaway K, Bernal-Hoyos E, Van Der Heiden M, Popma J, Keeney M. An optimized whole blood method for flow cytometric measurement of ZAP-70 protein expression in chronic lymphocytic leukemia. Cytometry B Clin Cytom 2006;70B:259-269.
18. Bakke AC, Purtzer Z, Leis J, Huang J. A robust ratio metric method for analysis of Zap-70 expression in chronic lymphocytic leukemia (CLL). Cytometry B Clin Cytom 2005;70B:227-234.
19. Del Giudice I, Morilla A, Osuji N, Matutes E, Morilla R, Burford A, Maravelaki S, Owusu-Ankomah K, Swansbury J, A'Hern R, Brito-Babapulle V, Catovsky D. Zeta-Chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. Cancer 2005;104:2124-2132.
20. Durig J, Nuckel H, Cremer M, Fuhrer A, Halfmeyer K, Fandrey J, Moroy T, Klein-Hitpass L, Duhrsen U. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003;17: 2426-2434.
21. Gibbs G, Bromidge T, Howe D, Hopkins J, Johnson S. Comparison of flow cytometric methods for the measurement of ZAP-70 expression in a routine diagnostic laboratory. Clin Lab Haematol 2005;27: 258-266.
22. Kay S, Herishanu Y, Pick M, Rogowski O, Baron S, Naparstek E, Polliack A, Deutsch VR. Quantitative flow cytometry of ZAP-70 levels in chronic lymphocytic leukemia using molecules of equivalent soluble fluorochrome. Cytometry B Clin Cytom 2006;70B:218-226.
23. Shenkin M, Maiese R. Use of a blocking antibody method for the flow cytometric measurement of ZAP-70 in B-CLL. Cytometry B Clin Cytom 2006;70B:251-258.
24. Sheridan R, Mounajjed T, Ehrmann DE, Hurtubise PE, Schrager JA. Comparison of bone marrow and peripheral blood ZAP-70 status examined by flow cytometric immunophenotyping in patients with chronic lymphocytic leukemia. Cytometry B Clin Cytom 2006;70B: 319-320.
25. Wilhelm C, Neubauer A, Brendel C. Discordant results of flow cytometric ZAP-70 expression status in B-CLL samples if different gating strategies are applied. Cytometry B Clin Cytom 2006;70B:242-250.
26. Sheikholeslami MR, Jilani I, Keating M, Uyeji J, Chen K, Kantarjian H, O'Brien S, Giles F, Albitar M. Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis. Cytometry B Clin Cytom 2006;70B:270-275.
27. Jacobberger JW. Intracellular antigen staining. Methods: A Companion Methods Enzymol 1991;2:207-218.
28. Shults KE, Miller DT, Davis BH, Flye L, Hobbs LA, Stelzer GT. A standardized ZAP-70 assay-Lessons learned in the trenches. Cytometry B Clin Cytom 2006;70B:276-283.
29. Chow S, Hedley D, Grom P, Magari R, Jacobberger JW, Shankey TV. Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations. Cytometry A 2005;67A:4-17.
30. Widen RH, Becker JL. Detection of intracellular/intranuclear antigens in tumor cells. Methods Mol Biol 1998;91:57-65.
31. Murphy R.F. Scatchard analysis by flow cytometry. In:Radburch A, editor. Flow Cytometry and Cell Sorting. Berlin: Springer-Verlag; 1992. pp 59-62.
32. Pitas RE, Innerarity TL, Arnold KS, Mahley RW. Rate and equilibrium constants for binding of apo-E HDLc (a cholesterol-induced lipoprotein) and low density lipoproteins to human fibroblasts: Evidence for multiple receptor binding of apo-E HDLc. Proc Natl Acad Sci USA 1979;76:2311-2315.
33. Yu H, Soong N, Anderson WF. Binding kinetics of ecotropic (Moloney) murine leukemia retrovirus with NIH 3T3 cells. J Virol 1995;69:6557-6562.
34. Zucchetto A, Bomben R, Bo MD, Nanni P, Bulian P, Rossi FM, Del Principe MI, Santini S, Del Poeta G, Degan M, Gattei V. ZAP-70 expression in B-cell chronic lymphocytic leukemia: Evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgV(H) mutations. Cytometry B Clin Cytom 2006;70B:284-292.
35. Bosch F, Muntanola A, Gine E, Carrio A, Villamor N, Moreno C, Crespo M, Montserrat E. Clinical implications of ZAP-70 expressionin chronic lymphocytic leukemia. Cytometry B Clin Cytom 2006; 70B:214-217.